Topic: Chutes and Ladders
Affimed has terminated its bispecific T-cell engager program after the FDA hit it with a clinical hold and shifted ts focus to innate cell engagers.
AZ nets exec to lead breast cancer R&D; Teva stars in price-fix plot, but attorneys general say others "willingly" joined; EUSA Pharma nabs new execs.
The R&D shake-up at AstraZeneca continues as it hires cancer researcher Dr. Sunil Verma to run its breast cancer work.
EUSA Pharma has added two biopharma veterans to its roster, one coming after being fired from his old job and the other a top Pfizer scientist.
Eisai installs new Alzheimer's clinical leadership team; Insys founder found guilty in landmark opioid suit; and Gilead's chief plots Kite CEO hire.
The hires provide Bicycle with clinical trial expertise at a time when it is contending with the resignation of its chief medical officer.
Mohammed Dar lines up as the latest AstraZeneca/MedImmune executive to jump ship into U.K. biotech Immunocore.
FogPharma has hired Howard Stern, M.D., Ph.D., as its new chief scientific officer and Peter Fekkes, Ph.D., as VP of discovery bioscience.
The medical devices director of the U.K. MHRA aims to retire this October, the second administrator to do so after the CEO in the wake of Brexit.
CMO Iannone walks out on Immunomedics; uBiome CEOs take leave following FBI raid; and Gilead’s longtime CFO announces plan to retire.